ROYALTY PHARMA INCREASES ALL CASH OFFER TO ACQUIRE ELAN TO $12.50 PER SHARE |
|
New York, NY – May 20, 2013 - Following its announces increased offer to $12.50 per share in cash under rule 2.5 of Irish takeover rules. All cash offer is fully financed, cash confirmed and not conditional on due diligence. The increased offer is conditional on Elan Stockholders voting against the Theravance transaction.
|
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING FORMAL CASH OFFER FOR ELAN |
|
New York, NY – May 2, 2013 - Following its announcements on the 15 April and 18 April, Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued an offer document dated 2 May 2013. In the Offer Document, Royalty Pharma confirms the Offer Price set forth in its Rule 2.5 Announcement of 15 April.
|
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING ELAN DUTCH AUCTION RESULT |
|
New York, NY – April 18, 2013 - Consistent with the terms of Royalty Pharma's announcement of a firm intention to make an offer dated 15 April 2013, Royalty Pharma confirms that its Offer Price is US$11.25 per Elan Share and Elan ADS.
|
ROYALTY PHARMA ANNOUNCES FIRM FULLY FINANCED OFFER TO ACQUIRE ELAN |
|
New York, NY – April 15, 2013 - Royalty Pharma announces a firm fully financed cash offer to acquire Elan under rule 2.5 of Irish takeover rules. The Offer is valued at up to US$12 per Elan Share, a 23 percent increase over the enterprise value of Royalty Pharma’s initial February 25, 2013 proposal. The terms of the Offer are determined by the outcome of Elan's recently launched Dutch Auction tender offer.
|
ROYALTY PHARMA STATEMENT REGARDING ELAN PROPOSAL |
|
New York, NY - March 6, 2013 - Royalty Pharma remains committed to acquiring Elan on the terms set out in the Proposal Announcement of February 25, 2013, but continues to be disappointed that the Board of Elan has not engaged in discussions. Royalty Pharma announces today that it is meeting with a number of Elan Shareholders to discuss the Proposal.
|
ROYALTY PHARMA PROPOSAL TO ACQUIRE ELAN CORPORATION, plc |
|
New York, NY – February 25, 2013 - Royalty Pharma is proposing, on an indicative basis, to make an offer for Elan of US$11 for every Elan Share and every Elan ADS. This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules.
|
ROYALTY PHARMA RAISES $600 MILLION OF DEBT |
New York, NY – May 24, 2012 - Royalty Pharma, the industry leader in acquiring royalty interests in
marketed and late stage biopharmaceutical products, announced that it has successfully issued $600
million of incremental Term Loan B debt through RPI Finance Trust (“RPIFT”), bringing total debt
outstanding at RPIFT to approximately $3.4 billion. Proceeds will be used to fund future acquisitions.
|
Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm |
New York, NY – May 2, 2012 - Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).
|
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement |
|
New York, NY and South San Francisco, CA – March 29, 2012 - Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis’ lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
|
Royalty Pharma Acquires Cimzia® and Mircera® Royalties for $124 million |
|
New York, NY – February 29, 2012 - Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million.
|
Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million |
|
San Francisco, CA – February 29, 2012 - Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million.
|
Royalty Pharma Raises $3.6 Billion to Refinance $2.75 Billion of Outstanding Debt and to Fund an $850 Million Cash Distribution to Shareholders |
|
New York, NY - September 07, 2011 - Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.
|
Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement |
|
Boston, MA – August 11, 2011 - Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million.
|
Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million |
|
Tokyo - June 30, 2011 - Astellas Pharma Inc. announced today that Prosidion’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of $609 million. The transaction is expected to close in July 2011.
|
Royalty Pharma Announces George Lloyd Joins Management Team |
|
New York, NY - May 18, 2011 - Royalty Pharma is pleased to announce that George Lloyd has joined
the company as Executive Vice President, Investments.
|
Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million |
|
New York, NY - April 4, 2011 - Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.
|
Cypress Bioscience Agrees to be Acquired by Ramius LLC and Royalty Pharma for $6.50 per Share in Cash |
|
San Diego, CA and New York, NY - December 15, 2010 - Cypress Bioscience, Inc. (Nasdaq: CYPB) ("Cypress"), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, announced today that it has entered into a definitive merger agreement with Ramius V&O Acquisition LLC, an affiliate of Ramius LLC (collectively, “Ramius”) and affiliates of Royalty Pharma (“Royalty Pharma”), providing for the acquisition of Cypress by Ramius and Royalty Pharma.
|
Royalty Pharma Announces Alexander von Perfall Joins Management Team |
|
New York, NY - December 7, 2009 - Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.
|
Royalty Pharma Announces James Reddoch, PhD Joins Management Team |
|
New York, NY - July 8, 2008 - Royalty Pharma is pleased to announce that James Reddoch, PhD has joined the company as Executive Vice President, Head of Research.
|
Royalty Pharma Acquires Royalty Interest in RotaTeq® from The Children’s Hospital Foundation for $182 Million |
|
New York, NY - April 23, 2008 - The Children’s Hospital Foundation, the parent company of The Children’s Hospital of Philadelphia® and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq® from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
|
|
